Rafferty Asset Management, LLC Bio Xcel Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$6.39 - $28.58 $310,055 - $1.39 Million	48,522 Added 32.54%	197,634 $1.32 Million
Q1 2023 May 11, 2023	BUY	$17.7 - $33.24 $2.64 Million - $4.96 Million	149,112 New	149,112 $2.78 Million
Q2 2022 Aug 12, 2022	SELL	$9.03 - $21.55 $839,139 - $2 Million	-92,928 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$15.0 - $22.83 $85,650 - $130,359	-5,710 Reduced 5.79%	92,928 $1.94 Million
Q4 2021 Feb 10, 2022	BUY	$20.12 - $35.09 $781,360 - $1.36 Million	38,835 Added 64.94%	98,638 $2.01 Million
Q3 2021 Nov 10, 2021	SELL	$23.84 - $32.03 $216,872 - $291,376	-9,097 Reduced 13.2%	59,803 $1.82 Million
Q2 2021 Aug 10, 2021	SELL	$29.06 - $38.83 $58,817 - $78,591	-2,024 Reduced 2.85%	68,900 $2 Million
Q1 2021 May 10, 2021	BUY	$39.04 - $64.6 $1.92 Million - $3.18 Million	49,300 Added 227.99%	70,924 $3.06 Million
Q4 2020 Feb 10, 2021	SELL	$42.46 - $56.58 $956,538 - $1.27 Million	-22,528 Reduced 51.02%	21,624 $999,000
Q3 2020 Nov 13, 2020	BUY	$37.44 - $64.63 $1.13 Million - $1.95 Million	30,192 Added 216.28%	44,152 $1.91 Million
Q2 2020 Aug 07, 2020	BUY	$17.62 - $58.71 $245,975 - $819,591	13,960 New	13,960 $740,000

3.14M

22.2K

40.2K

Ticker BTAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,022,500
Market Cap $12.6M
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.